Antimicrobial spectrum

Global Sepsis Therapeutics Strategic Research Report 2023-2024 and 2030: New Nanoparticles - A Revolution in the Development of Clinical Sepsis Therapy - ResearchAndMarkets.com

Retrieved on: 
수요일, 4월 24, 2024

The "Sepsis Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sepsis Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • Common treatments for sepsis include antibiotics and vasopressors, with cephalosporins holding a significant share of the treatment market.
  • Despite the global economic update, the competitive landscape of the sepsis therapeutics market remains strong, with players worldwide categorized by their market presence.
  • The current standard of care involves antibiotics and vasopressors, with GIAPREZA being the only FDA-approved branded drug for sepsis treatment.

Don't Miss Out - Join the 7th IFPA Conference: Uncovering the Broad Spectrum of Psoriatic Disease

Retrieved on: 
목요일, 4월 11, 2024

This year's conference promises to be a pivotal event for experts and stakeholders in the field of psoriatic disease, under the theme "Uncovering the Broad Spectrum of Psoriatic Disease."

Key Points: 
  • This year's conference promises to be a pivotal event for experts and stakeholders in the field of psoriatic disease, under the theme "Uncovering the Broad Spectrum of Psoriatic Disease."
  • We are honored to have April Armstrong, Chair of the Scientific Executive Committee (SEC), as the President of the 7th IFPA Conference.
  • By attending workshops, seminars, and keynote presentations, participants can enhance their knowledge and skills in various aspects of psoriatic disease.
  • Engage with leading experts, participate in insightful discussions, and contribute to shaping the future of psoriatic disease research and advocacy.

Don't Miss Out - Join the 7th IFPA Conference: Uncovering the Broad Spectrum of Psoriatic Disease

Retrieved on: 
목요일, 4월 11, 2024

This year's conference promises to be a pivotal event for experts and stakeholders in the field of psoriatic disease, under the theme "Uncovering the Broad Spectrum of Psoriatic Disease."

Key Points: 
  • This year's conference promises to be a pivotal event for experts and stakeholders in the field of psoriatic disease, under the theme "Uncovering the Broad Spectrum of Psoriatic Disease."
  • We are honored to have April Armstrong, Chair of the Scientific Executive Committee (SEC), as the President of the 7th IFPA Conference.
  • By attending workshops, seminars, and keynote presentations, participants can enhance their knowledge and skills in various aspects of psoriatic disease.
  • Engage with leading experts, participate in insightful discussions, and contribute to shaping the future of psoriatic disease research and advocacy.

JKA Supplier Diversity Solutions Achieves No. 143 Ranking on Inc. Magazine's 2024 Inc. 5000 Regionals

Retrieved on: 
토요일, 3월 2, 2024

NEW YORK, March 2, 2024 /PRNewswire-PRWeb/ -- Celebrating a significant milestone, JKA Supplier Diversity Solutions, at the forefront of supplier diversity consulting, proudly announces its prestigious ranking of No. 143 on the Inc. 5000 Regionals: Northeast list for 2024. Achieving an impressive two-year revenue growth of 103%, the company has been instrumental in fostering inclusive economic growth by facilitating meaningful connections between government agencies, corporations, and a broad spectrum of diverse businesses. This recognition by Inc. magazine positions JKA Supplier Diversity Solutions as a vital player in promoting supplier diversity initiatives across the Northeast region.

Key Points: 
  • Consulting Expert Consultancy Enhances Supplier Diversity Programs for Fortune 500 Companies, Connecting Them with a Broad Spectrum of Diverse Businesses
    NEW YORK, March 2, 2024 /PRNewswire-PRWeb/ -- Celebrating a significant milestone, JKA Supplier Diversity Solutions, at the forefront of supplier diversity consulting, proudly announces its prestigious ranking of No.
  • This recognition by Inc. magazine positions JKA Supplier Diversity Solutions as a vital player in promoting supplier diversity initiatives across the Northeast region.
  • JKA Supplier Diversity Solutions specializes in comprehensive supplier diversity consulting services, including outreach, compliance, and training.
  • For further details about JKA Supplier Diversity Solutions and its mission to transform supplier diversity practices, visit www.jkasolutions.com

Human medicines European public assessment report (EPAR): Quofenix, delafloxacin, Date of authorisation: 16/12/2019, Revision: 6, Status: Authorised

Retrieved on: 
화요일, 1월 2, 2024

Human medicines European public assessment report (EPAR): Quofenix, delafloxacin, Date of authorisation: 16/12/2019, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Quofenix, delafloxacin, Date of authorisation: 16/12/2019, Revision: 6, Status: Authorised

Consumption of antimicrobials in animals reaches lowest level ever in Europe

Retrieved on: 
월요일, 12월 18, 2023

Overall sales of veterinary antibiotics decreased by 53% between 2011 and 2022, reaching the lowest level ever reported, according to data from 25 countries.

Key Points: 
  • Overall sales of veterinary antibiotics decreased by 53% between 2011 and 2022, reaching the lowest level ever reported, according to data from 25 countries.
  • This is one of the key findings of the thirteenth annual report on the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC): 2009 - 2023.
  • EMA has been monitoring sales of veterinary antimicrobials in Europe through the ESVAC project since 2009, when 9 European countries volunteered to provide data on sales of veterinary antimicrobials.
  • ESVAC has led to the collection of reliable data on antimicrobials sold for use in animals, providing invaluable insights for participating countries on the impact of their measures to promote the prudent use and setting targets to reduce the consumption of antimicrobials in animals.

How do bacteria actually become resistant to antibiotics?

Retrieved on: 
수요일, 11월 8, 2023

“What doesn’t kill me makes me stronger”, originally coined by Friedrich Nietzsche in 1888, is a perfect description of how bacteria develop antibiotic resistance.

Key Points: 
  • “What doesn’t kill me makes me stronger”, originally coined by Friedrich Nietzsche in 1888, is a perfect description of how bacteria develop antibiotic resistance.
  • Contrary to a common belief, antibiotic resistance is not about your body becoming resistant to antibiotics.

How bacteria adapt

  • The ability for bacteria to adapt lies in part with their astonishing rate of reproduction.
  • While most changes are bad, sometimes they can help the bacteria grow in the presence of an antibiotic.
  • This evolution of resistance can be seen by growing bacteria on a large agar plate (a nutrient support that bacteria like to grow on) with zones of increasing antibiotic levels.

They also exchange genetic material

  • The other key mechanism enabling bacterial resistance is the exchange of genetic information between bacteria.
  • In addition to the main chunk of DNA that encodes the bacterial genome, bacteria can host circular DNA snippets called plasmids.
  • Plasmid exchange usually occurs by direct physical contact between bacteria.

4 ways bacteria resist

  • Gram-positive bacteria like Staphylococcus aureus have a thick cell wall enclosing a lipid membrane.
  • Antibiotics can hijack these entry routes, but bacteria can modify the cell wall, cell membrane and entry proteins to block antibiotic penetration.
  • For example, bacteria increase the thickness of the cell wall to resist antibiotics like vancomycin.
  • Bacteria have machinery known as efflux pumps, which regurgitate unwanted molecules from within the bacteria.
  • Bacteria can alter the pump so it is more effective at removing the antibiotic, or they can simply make more pumps.
  • Antibiotics, like most other drugs, generally work by blocking the function of important enzymes within the bacteria.
  • If bacteria alter the target shape by changing the DNA/protein sequence, the antibiotic (key) can no longer bind to its target (lock).

Bacteria vs antibiotics

  • While bacteria have developed mechanisms to resist antibiotics, these adaptations can come at a “fitness” cost.
  • Bacteria may grow more slowly, or can be killed more easily by another antibiotic.
  • This has led to the concept of “collateral sensitivity” to prevent or overcome resistance when treating patients, by using pairs of antibiotics.


Mark Blaskovich receives funding from a range of government, not-for-profit and commercial organisations for research into antibiotic discovery and development. He is affiliated with AAMRNet (Australian Antimicrobial Resistance Network), an organisation promoting improved care and development of antibiotics and antibiotic alternatives.

Registration for the 7th IFPA Conference 2024 now open

Retrieved on: 
화요일, 11월 7, 2023

STOCKHOLM, Nov. 7, 2023 /PRNewswire/ -- IFPA (International Federation of Psoriasis Associations) is thrilled to announce the 7th IFPA Conference (former World Psoriasis & Psoriatic Arthritis Conference), set to take place from June 27 to 29, 2024, in the vibrant city of Stockholm, Sweden.

Key Points: 
  • STOCKHOLM, Nov. 7, 2023 /PRNewswire/ -- IFPA (International Federation of Psoriasis Associations) is thrilled to announce the 7th IFPA Conference (former World Psoriasis & Psoriatic Arthritis Conference), set to take place from June 27 to 29, 2024, in the vibrant city of Stockholm, Sweden.
  • This year's conference theme, "Uncovering the Broad Spectrum of Psoriatic Disease," reflects the mission of IFPA to increase global recognition of the seriousness of psoriatic disease.
  • The IFPA Conference is a unique platform where delegates can explore psoriatic disease from various perspectives by networking with patients and industry representatives in attendance.
  • At the upcoming IFPA conference in Stockholm, we will share our knowledge and have meaningful conversations about these advances".

Registration for the 7th IFPA Conference 2024 now open

Retrieved on: 
화요일, 11월 7, 2023

STOCKHOLM, Nov. 7, 2023 /PRNewswire/ -- IFPA (International Federation of Psoriasis Associations) is thrilled to announce the 7th IFPA Conference (former World Psoriasis & Psoriatic Arthritis Conference), set to take place from June 27 to 29, 2024, in the vibrant city of Stockholm, Sweden.

Key Points: 
  • STOCKHOLM, Nov. 7, 2023 /PRNewswire/ -- IFPA (International Federation of Psoriasis Associations) is thrilled to announce the 7th IFPA Conference (former World Psoriasis & Psoriatic Arthritis Conference), set to take place from June 27 to 29, 2024, in the vibrant city of Stockholm, Sweden.
  • This year's conference theme, "Uncovering the Broad Spectrum of Psoriatic Disease," reflects the mission of IFPA to increase global recognition of the seriousness of psoriatic disease.
  • The IFPA Conference is a unique platform where delegates can explore psoriatic disease from various perspectives by networking with patients and industry representatives in attendance.
  • At the upcoming IFPA conference in Stockholm, we will share our knowledge and have meaningful conversations about these advances".

Resistance to antibiotics in northern Nigeria: what bacteria are prevalent, and which drugs work against them

Retrieved on: 
일요일, 9월 17, 2023

Antimicrobial resistance – the ability of microorganisms to resist drugs that have been developed to control them – is a severe problem in African countries.

Key Points: 
  • Antimicrobial resistance – the ability of microorganisms to resist drugs that have been developed to control them – is a severe problem in African countries.
  • The continent has the highest global burden of antimicrobial-resistant infections, with 114.8 deaths per 100,000 people.
  • Physicians need laboratory data to choose the right antibiotic, at the right dose, for the right period of time.
  • This can lead to choosing ineffective antibiotics, which can lead to increases in resistant bacteria.
  • In other words, to develop a list of what bacteria are prevalent in the region and which drugs work against them.
  • To accomplish this, we recently conducted a study of multidrug-resistant bacteria obtained from patients in six hospitals in northern Nigeria.

Drug-resistant bacteria in Nigeria

    • We chose to analyse bacteria that are resistant to more than one drug because they are the biggest challenge when treating infections.
    • We found that about 85% of the bacteria isolated from infections were resistant to the most commonly used antibiotics.
    • The good news was that two antibiotics, tigecycline and fosfomycin, remained very active even against highly resistant strains of bacteria.

Genetic mechanisms

    • This was done to understand what made these organisms so resistant to antibiotics at the molecular level.
    • The data revealed an astonishingly high number of genetic mechanisms making the microorganisms resistant.
    • In some cases, the genetic information encoding resistance was capable of being shared among other microorganisms.

The need for antimicrobial stewardship

    • Some of the resistance genes were capable of moving from one microorganism to another (mobile resistance genes).
    • Antimicrobial stewardship based on laboratory data is effective especially if done locally, regionally and nationally.

Antimicrobial resistance is everyone’s concern

    • Read more:
      Antimicrobial resistance calls for brainpower of a space agency and campaigning zeal of an NGO

      Fourth, there are things that everyone can do to help bring antibiotic resistance under control.

    • For example, the US Centers for Disease Control and Prevention list five things that everyone should know about drug resistance and 10 activities to protect yourself and your family against resistance.
    • He is affiliated with the International Society for Antimicrobial Chemotherapy.